Natera, Inc. (NASDAQ:NTRA) had its price target lowered by analysts at Morgan Stanley from $18.00 to $13.00 in a report issued on Monday. The firm presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s target price would indicate a potential upside of 56.82% from the company’s current price.

Several other analysts have also recently weighed in on NTRA. BidaskClub cut Natera from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. ValuEngine cut Natera from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Canaccord Genuity boosted their price objective on Natera from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Wednesday, May 10th. Finally, Zacks Investment Research cut Natera from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Four investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $14.80.

Natera (NASDAQ:NTRA) traded down 5.19% during trading on Monday, hitting $7.86. 21,398 shares of the stock traded hands. The firm’s 50-day moving average is $10.36 and its 200 day moving average is $9.58. The stock’s market cap is $415.65 million. Natera has a 52 week low of $7.35 and a 52 week high of $13.08.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.09. The firm had revenue of $46.90 million for the quarter, compared to the consensus estimate of $42.82 million. Natera had a negative return on equity of 101.63% and a negative net margin of 60.89%. The business’s revenue for the quarter was down 24.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.17) earnings per share. Equities research analysts forecast that Natera will post ($2.01) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/07/morgan-stanley-lowers-natera-inc-ntra-price-target-to-13-00.html.

Several hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. bought a new stake in shares of Natera during the fourth quarter worth approximately $130,000. State Street Corp boosted its stake in shares of Natera by 2.9% in the fourth quarter. State Street Corp now owns 389,498 shares of the medical research company’s stock worth $4,561,000 after buying an additional 11,067 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Natera by 51.4% in the fourth quarter. Renaissance Technologies LLC now owns 320,800 shares of the medical research company’s stock worth $3,757,000 after buying an additional 108,900 shares during the period. Teachers Advisors LLC boosted its stake in shares of Natera by 5.0% in the fourth quarter. Teachers Advisors LLC now owns 44,224 shares of the medical research company’s stock worth $518,000 after buying an additional 2,116 shares during the period. Finally, Highbridge Capital Management LLC boosted its stake in shares of Natera by 119.7% in the fourth quarter. Highbridge Capital Management LLC now owns 41,686 shares of the medical research company’s stock worth $488,000 after buying an additional 22,712 shares during the period. 59.74% of the stock is owned by institutional investors.

About Natera

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.